The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
 
Lajos Pusztai
Honoraria - Athenex; bioTheranostics; natera; OncoCyte
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies
 
Jess R Hoag
Employment - Exact Sciences
Stock and Other Ownership Interests - AstraZeneca; Exact Sciences; Lilly; Novo Nordisk; UnitedHealthcare
 
Kathy S. Albain
Honoraria - Encore Medical Education
Research Funding - Quantum Leap Healthcare Collaborative (Inst); Seagen (Inst)
Other Relationship - Seagen
 
William E. Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Salomon M. Stemmer
No Relationships to Disclose
 
Allison Meisner
No Relationships to Disclose
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Novartis; Seagan
 
Steven Shak
Employment - Exact Sciences; Roche (I)
Leadership - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
Consulting or Advisory Role - Exact Sciences; Genomic Life
Patents, Royalties, Other Intellectual Property - Filed Oncotype DX patents (Inst)
 
Daniel F. Hayes
Stock and Other Ownership Interests - Cellworks; InBiomotion; Xilis
Honoraria - Tempus
Consulting or Advisory Role - Artera; Arvinis; bioTheranostics; BioVica; Cellworks; Centrix; Cepheid; Epic Sciences; Exact Sciences; Freenome; Guardant Health; L-Nutra; Macrogenics; Oncocyte; Strata Oncology; Stratipath; Tempus; Turnstone Bio; xilis
Research Funding - Angle (Inst); AstraZeneca (Inst); Cepheid/Danaher (Inst); Menarini Silicon Biosystems (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Cancer Expert Now; UpToDate
 
James M. Rae
No Relationships to Disclose
 
Frederick Baehner
Employment - Exact Sciences
Leadership - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
 
Priyanka Sharma
Stock and Other Ownership Interests - Amgen; Gilead Sciences (I); Johnson & Johnson/Janssen; Pfizer (I); Roche/Genentech (I); Sanofi
Consulting or Advisory Role - AstraZeneca; Boston Scientific (I); Cipla (I); Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Salient Pharmaceuticals (I); Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics